Manama: A study conducted in Bahrain has found the Sinopharm vaccine to be less effective in elderly vaccinated Covid-19 positive patients.
The study has found that the percentage of deaths among all PCR positive post-vaccination Covid-19 cases among recipients of the Sinopharm vaccine was 0.46 per cent (i.e., 112 deaths) versus 0.15 per cent for Pfizer-BioNTech (i.e., 3 deaths) and 0.03 per cent for Covishield-AstraZeneca (1 death).
The authors have concluded that the four vaccines effectively reduced all four outcomes (infections, hospitalisations, ICU admissions, and deaths) in vaccinated compared to unvaccinated individuals, before and during the period when the Delta variant became dominant in the country.
After censoring early vaccine recipients of the Sinopharm vaccine, compared to Pfizer-BioNTech recipients, individuals vaccinated with Sinopharm had a higher risk of post-vaccination infections, hospitalisations, ICU admissions, and deaths, especially in those above 50 years old, according to the published by Research Square.
The study backs the importance of vaccination in preventing Covid-19 related events, even after the emergence of the Delta variant.